CRISPR Screens Identify T Cell Targets in Solid Tumors

Researchers have developed a novel in vivo model capable of recovering human T cells directly from solid tumors, a breakthrough that allows for genome-wide CRISPR screens to identify specific targets for improving CAR T cell antitumour activity. This new methodology, detailed in a publication in Nature on August 12, 2026, addresses a critical limitation in current cancer immunotherapy research, where understanding the complex tumor microenvironment and its impact on T cell function has been challenging.

The study utilized CRISPR-Cas9 gene editing technology to systematically inactivate genes within human T cells. These modified T cells were then introduced into solid tumors in a preclinical setting. By analyzing which T cells survived and proliferated within the tumor microenvironment, the researchers could pinpoint genes and pathways that are essential for T cell function and survival in the presence of cancer. Conversely, inactivating certain genes led to enhanced T cell activity against the tumor, highlighting them as potential therapeutic targets.

This in vivo screening approach offers a significant advantage over traditional in vitro methods, which often fail to replicate the intricate biological interactions and immunosuppressive factors present within a solid tumor. The ability to perform these screens directly within the tumor allows for the identification of targets that are relevant to the actual therapeutic context. The findings from these screens can guide the development of next-generation CAR T cell therapies, potentially by engineering T cells with enhanced resistance to tumor-induced exhaustion or by identifying combination strategies that overcome tumor-specific immune evasion mechanisms.

The implications of this research extend to a broad range of solid tumors, including notoriously difficult-to-treat cancers. By uncovering new vulnerabilities within the tumor microenvironment that T cells can exploit, or by identifying ways to bolster T cell resilience, this work paves the way for more effective and durable responses to CAR T cell therapy. The publication's DOI is 10.1038/s41586-026-10906-9, providing a verifiable reference for the scientific community to access the detailed methodology and results of this pioneering study. Further research will likely focus on translating these identified targets into clinical applications, aiming to bring improved cancer treatments to patients.